Centient Biotech Investor Top 10 List

SAN DIEGO, Oct. 19 /PRNewswire/ -- The Centient Biotech Investor(TM), a newsletter and website for professional investors in public and private biotechnology companies, has announced its Centient Top 10 Biotech list, identifying the ten companies it believes will outperform the biotechnology sector as a whole over the next twelve months.

The Centient Biotech Top 10 includes both industry pioneers and emerging companies that are far from household names. They have been identified as key stocks based on their product pipelines, clinical successes and the market potential for their lead drugs or candidates. The full report is available online at www.BiotechInvestor.com.

"Our Top 10 list is very interesting in its diversity," said Greg Scott, the founder and principal analyst for The Centient Biotech Investor. "The companies we have selected as 'the most likely to succeed' run the gamut from Genentech and Amgen, solid, integrated companies with blockbuster drugs, strong earnings growth and extensive pipelines, to StemCells and Geron, highly speculative, momentum plays full of promise but as yet unproven."

The Centient Biotech Investor has been publishing investment analysis and advice for nearly two years and registering a high percentage of accurate calls, but this is the first time the newsletter has gone on record with a specific list of recommended companies. "The one thing all of our Top 10 biotechs have in common is that we expect each of them to do well over the next twelve months. But biotech is a volatile industry, and a single disappointing clinical trial or major adverse advent can quickly turn a winner into a loser, so only time will tell," said Frank Eeckman MD, PhD, editor of The Centient Biotech Investor.

To date, the newsletter has succeeded in identifying trends that have had a major impact on the industry as a whole -- weeks in advance of general recognition by the market. For example, its reports were uncannily specific in predicting a month ahead of the news story, that Vioxx would be pulled from the shelves and that the issues with Vioxx were likely to hit other Cox-2 inhibitors such as Pfizer's Bextra. The newsletter also has suggested positive news in advance, revealing that UCB was on the lookout for M&A partners two weeks before of its acquisition of Celltech, the largest acquisition ever in Europe.

"We believe we understand the biotechnology industry better than most," said Scott. "With our combined scientific, financial and investment expertise, and our inside knowledge of this complex industry, we think we have the best tools to separate the winners from the losers."

Principal analysts at The Centient Biotech Investor are Greg Scott, founder, and Frank Eeckman, MD, PhD. Dr. Eeckman's background includes senior positions at ParkeDavis/Pfizer and he has helped launch three biotechnology companies. He was head of bioinformatics for the Human Genome Project at Lawrence Berkeley National Laboratory and is a sought after consultant to industry and venture capitalists. Greg Scott is the founder of Centient Consulting, Inc., publishers of The Centient Biotech Investor, and president and co-founder of Life Science Angels, Inc., an angel investment group focusing on early stage biotechnology and medical device companies. He previously founded three technology companies and held executive positions with MCI, Price Waterhouse and Capgemini.

The Centient Biotech Top 10 may be viewed in its entirety on the Centient newsletter website: www.BiotechInvestor.com. In addition, the CBTT10(TM) index, created to track the Top 10 recommendations, is available on the website. The CBTT10 may also be compared to the Centient Biotech 200(TM) index, the CBT200(TM), to determine how the Top 10 list is performing against the biotechnology industry as a whole.

By special arrangement with BioSpace, the full Centient Biotech Top 10 report and the CBTT10 index may also be viewed on the BioSpace website beginning Thursday, at www.biospace.com.

About The Centient Biotech Investor(TM):

The Centient Biotech Investor(TM) is a San Diego and Berkeley, California-based newsletter and website providing professional investors and investment advisors with analysis on public and private biotechnology companies. The Centient Biotech Investor was created in March, 2001, by Greg Scott and Frank H. Eeckman, MD, PhD, consultants to fund managers, venture capitalists and biotechnology companies, to meet the need for objective, unbiased investment guidance. Mr. Scott and Dr. Eeckman, with senior analyst Richard Daverman, PhD, publish industry and company analysis daily on Centient's subscription website, www.BiotechInvestor.com, and in the Centient Daily Update, a free email newsletter. They also publish a number of special reports on the biotechnology industry and the underlying science. All of Centient's publications are targeted specifically to professional investors and investment advisors who manage portfolios that include biotechnology companies.

Source: Centient Biotech Investor

Back to news